Grant: CAAIF/CIHR-III/CIHR-ICRH Food Allergy Research Grant
McMaster University
$100,000.00
Multi-omic characterization of memory B cell reprogramming during oral immunotherapy and outgrowth of food allergy
FY 2023-24
Summary
Allergies against some foods, like peanut and shellfish, tend to be lifelong in most people. However, allergies against others, like egg and milk, are outgrown by most people by the teenage years. These allergies are caused by IgE antibodies that are made only by allergic individuals. How those IgE antibodies are produced for a lifetime remains an area of active scientific inquiry. We recently discovered a type of cell called a type 2 memory B cell (MBC2) which we determined is responsible for making IgE antibodies when an allergic individual is exposed to their food allergen, and which we think is a key player in keeping people allergic to a food. A central objective moving forward is to create therapies that target this cell. However, we are not yet sure what type of MBC would be ideal to generate as an alternative to the MBC2.
In this proposal, we seek to use two conditions where allergic reactions to foods wane to understand what type of MBC should be the objective of therapy. Firstly, we seek to understand what type of MBC is generated during oral immunotherapy (OIT), an experimental therapy that involves consuming allergen in increasing amounts to increase the threshold for an allergic reaction. A central limitation of OIT is that those who stop the therapy tend to relapse to allergy. The second context is natural outgrowth of food allergy, which tends to be a permanent state of tolerance to the allergen. We hypothesize that OIT partially reprograms MBCs, but that MBC2s remain which can regenerate IgE and cause allergy. In contrast, we hypothesize that those who outgrow food allergy mostly reprogram their MBC2s towards a type of MBC that allows for tolerance of the food allergen. We seek to characterize this type of MBC, which will become our target outcome for novel therapies in food allergy.
To address this hypothesis, we will use samples from a clinical trial called PISCES in which patients were on OIT for up to 5 years, and recruit a new cohort of individuals who outgrew their food allergy. We will use unique tools called "allergen tetramers" which allow us to find and study MBCs that are specific for food allergens. We will then perform state-of-the-art analyses that allow us to study all of the genes that these MBCs are using and many of the proteins that the cells have made. Using complex computational tools, we will carefully cluster together cells that are similar and identify which clusters are present prior to OIT, during mid to long-term OIT, and after outgrowing a food allergy. This approach will allow us to study the MBC2 cells in these contexts, but also provide a very rich understanding of exactly what the ideal MBCs induced by therapy should be making.
Department
Program
CAAIF/CIHR-III/CIHR-ICRH Food Allergy Research Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
498188
Name
Koenig Joshua F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases
Projecttitle
Multi-omic characterization of memory B cell reprogramming during oral immunotherapy and outgrowth of food allergy
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CAAIF/CIHR-III/CIHR-ICRH Food Allergy Research Grant
Keyworddelim
Allergy Outgrowth; Food Allergy; Memory B Cells; Multi-Omic Analysis; Oral Immunotherapy
Abstract
Allergies against some foods, like peanut and shellfish, tend to be lifelong in most people. However, allergies against others, like egg and milk, are outgrown by most people by the teenage years. These allergies are caused by IgE antibodies that are made only by allergic individuals. How those IgE antibodies are produced for a lifetime remains an area of active scientific inquiry. We recently discovered a type of cell called a type 2 memory B cell (MBC2) which we determined is responsible for making IgE antibodies when an allergic individual is exposed to their food allergen, and which we think is a key player in keeping people allergic to a food. A central objective moving forward is to create therapies that target this cell. However, we are not yet sure what type of MBC would be ideal to generate as an alternative to the MBC2.
In this proposal, we seek to use two conditions where allergic reactions to foods wane to understand what type of MBC should be the objective of therapy. Firstly, we seek to understand what type of MBC is generated during oral immunotherapy (OIT), an experimental therapy that involves consuming allergen in increasing amounts to increase the threshold for an allergic reaction. A central limitation of OIT is that those who stop the therapy tend to relapse to allergy. The second context is natural outgrowth of food allergy, which tends to be a permanent state of tolerance to the allergen. We hypothesize that OIT partially reprograms MBCs, but that MBC2s remain which can regenerate IgE and cause allergy. In contrast, we hypothesize that those who outgrow food allergy mostly reprogram their MBC2s towards a type of MBC that allows for tolerance of the food allergen. We seek to characterize this type of MBC, which will become our target outcome for novel therapies in food allergy.
To address this hypothesis, we will use samples from a clinical trial called PISCES in which patients were on OIT for up to 5 years, and recruit a new cohort of individuals who outgrew their food allergy. We will use unique tools called "allergen tetramers" which allow us to find and study MBCs that are specific for food allergens. We will then perform state-of-the-art analyses that allow us to study all of the genes that these MBCs are using and many of the proteins that the cells have made. Using complex computational tools, we will carefully cluster together cells that are similar and identify which clusters are present prior to OIT, during mid to long-term OIT, and after outgrowing a food allergy. This approach will allow us to study the MBC2 cells in these contexts, but also provide a very rich understanding of exactly what the ideal MBCs induced by therapy should be making.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Koenig, Joshua F
Approvedterm
1 an 0 mois
Cihrcontribution2
III~ $100,000~ $0~